Drug profile · INN
trimetrexate glucuronate
NEUTREXIN
trimetrexate glucuronate (NEUTREXIN) is a dihydrofolate reductase inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — trimetrexate glucuronate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
trimetrexate glucuronate (NEUTREXIN) is a dihydrofolate reductase inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydrofolate reductase inhibitor
Primary target: Dihydrofolate reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is trimetrexate glucuronate?
trimetrexate glucuronate (NEUTREXIN) is a dihydrofolate reductase inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for trimetrexate glucuronate?
NEUTREXIN is a marketed brand name for trimetrexate glucuronate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trimetrexate glucuronate?
trimetrexate glucuronate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.